Page 25 - Inaugural HKU Urology Congress program book (high resolution) 2026 0723

Prostate Biopsy and Focal Therapy Solutions
Tel: (852) 2604 9389 Email: general@amscl.com

FEATURED SYSTEMS

CuraWay PoriNova™ IRE System
Curaway® Disposable Biopsy Needle
What it's for
Uses short high-voltage pulses to non-thermally ablate What it's for
prostate cancer tissue while sparing nearby nerves and vessels Single-use, spring-loaded biopsy needle
OTHER UROLOGICAL PRODUCTS

Artemis™ TPO System DUOLITH® SD1 T-TOP »ultra«

What it's for What it's for
Fuses prior MRI scans with live ultrasound to Extracorporeal shockwave therapy

guide precise, targeted prostate biopsy for urological and musculoskeletal MODULITH® SLX-F2 »FD21«
sampling in real time for men with MRI- indications. What it's for
flagged lesions or elevated PSA.
Extracorporeal shock wave lithotripsy system

Dosages:

1, 3, 6 months for

treatment flexibility

S

D
A
N
A
Y
D
T
O
T

U
T
H
A
R
S
E
N
D
’
I
T
W
G

C
a
P
H

N
A
N
M
S

V
I
I

L
T
C
A
K
O
B
H
T THE BACKBONE THERAPY THAT UNDERSTANDS TODAY’S MAN LIVING WITH PCa 1
E
B

N
A
R
E

Y
P
H

E
T
References: 1.Caffo O, et al. Glob Reg Health Technol Assess. 2024;11:207–213
DIPHERELINE® Hong Kong Abridged Package Insert (Refer to full prescribing information before prescribing)
Trade Name: DIPHERELINE® P.R. 3.75mg/11.25mg/22.5mg. INN: Triptorelin Presentations: Powder and solvent for intramuscular injections, 28-day or 3-month or 6-month prolonged release form. This pack contains a glass vial of powder,
an ampoule of 2 ml solvent, 1 syringe and 2 needles. Posology & Administration: Prostate Cancer: one intramuscular injection every 4 weeks (PR 3.75) or every 3 months (PR 11.25) or every 6 months (PR 22.5). Endometriosis: one
intramuscular injection every 4 weeks (PR 3.75) or every 3 months (PR 11.25) – treatment must be initiated in the first 5 days of the menstrual cycle and should not be administered for more than 6 months. Uterine fibromyomas prior to
surgery (PR 3.75): one intramuscular injection every 4 weeks – treatment must be initiated in the first 5 days of the menstrual cycle, treatment must not exceed 3 months. Precocious puberty (PR 3.75): before 8 years in girls and 10 years in
boys – children under 20kg: half the dose of DIPHERELINE PR 3.75 every 28 days; children between 20kg- 30kg: 2/3 of the dose of DIPHERELINE PR 3.75 every 28 days; children more than 30kg: one intramuscular injection of DIPHERELINE
PR 3.75mg every 28 days. (PR 11.25, PR 22.5) before 8 years in girls and 10 years in boys, one intramuscular injection every 3 or 6 months. Female infertility (PR 3.75): supplementary treatment in combination with gonadotrophins, one
injection of DIPHERELINE PR 3.75mg on the 2nd day of the cycle – gonadotrophins should be started generally 15 days after the injection. Contraindications: Hypersensitivity to gonadotropin-releasing hormone (GnRH), its analogues or to
any of the excipients; pregnancy. Special Warnings & Precautions: Non-pregnancy should be confirmed before prescription. Treatments may cause reduction in bone mineral density; may reveal the presence of a previously unknown
gonadotroph cell pituitary adenoma; mood changes, incl. depression have been reported. Caution should be given to patients treated with anti-coagulants. In men: DIPHERELINE causes a transient increase in serum testosterone levels, which
should be checked periodically. Caution should be given to patients with prostate cancer; spinal metastases; urinary tract obstruction; additional risk factors of osteoporosis, diabetes and certain cardiovascular diseases. In women: Every 4- DIP-HK-000498
week administration results in constant hypogonadotropic amenorrhoea. If genital haemorrhage occurs after the first month, plasma oestradiol levels should be measured and if levels are below 50 pg/ml, possible organic lesions should be
investigated. In female infertility, the follicular retrieval induced by the injection combined with gonadotrophins may increase markedly in some predisposed patients and particularly in cases of polycystic ovarian disease. The induced ovulation
should be monitored closely. Interactions: When triptorelin is used in combination with drugs that modify the secretion of pituitary gonadotropins, special precautions must be taken and it is recommended to closely monitor with hormone
assays. Undesirable Effects: In men: urinary symptoms, bone pain of metastatic origin and symptoms associated with, hot flushes, decreased libido, paresthesia in lower limbs, hyperhidrosis, asthenia, back pain. In women: exacerbation of
endometriosis symptoms, metrorrhagia, hot ushes, vaginal dryness, decreased libido and dyspareunia. In both: allergic reactions such as urticaria, rash, pruritus, nausea, vomiting, weight gain, hypertension, mood disorders, visual disturbances,
pain at the injection site and fever.
Revision date: 7 July 2026
IPSEN Pharma (Hong Kong)
34/F, Tower 1, Times Square, Causeway Bay, Hong Kong
Tel: 2637 8898 Fax: 2637 3987 http://www.ipsen.com